[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL2760463T3 - Regulacja kanałów sodowych przez białka PLUNC - Google Patents

Regulacja kanałów sodowych przez białka PLUNC

Info

Publication number
PL2760463T3
PL2760463T3 PL12833524T PL12833524T PL2760463T3 PL 2760463 T3 PL2760463 T3 PL 2760463T3 PL 12833524 T PL12833524 T PL 12833524T PL 12833524 T PL12833524 T PL 12833524T PL 2760463 T3 PL2760463 T3 PL 2760463T3
Authority
PL
Poland
Prior art keywords
regulation
sodium channels
plunc proteins
plunc
proteins
Prior art date
Application number
PL12833524T
Other languages
English (en)
Inventor
Robert Tarran
Monroe Jack Stutts
Scott Donaldson
Original Assignee
Univ North Carolina Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina Chapel Hill filed Critical Univ North Carolina Chapel Hill
Publication of PL2760463T3 publication Critical patent/PL2760463T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL12833524T 2011-09-20 2012-09-19 Regulacja kanałów sodowych przez białka PLUNC PL2760463T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161536647P 2011-09-20 2011-09-20
EP12833524.7A EP2760463B1 (en) 2011-09-20 2012-09-19 Regulation of sodium channels by plunc proteins
PCT/US2012/056112 WO2013043720A1 (en) 2011-09-20 2012-09-19 Regulation of sodium channels by plunc proteins

Publications (1)

Publication Number Publication Date
PL2760463T3 true PL2760463T3 (pl) 2019-05-31

Family

ID=47914825

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12833524T PL2760463T3 (pl) 2011-09-20 2012-09-19 Regulacja kanałów sodowych przez białka PLUNC

Country Status (13)

Country Link
US (2) US9127040B2 (pl)
EP (1) EP2760463B1 (pl)
AU (2) AU2012312520A1 (pl)
BR (1) BR112014006535A2 (pl)
CA (1) CA2849267A1 (pl)
DK (1) DK2760463T3 (pl)
ES (1) ES2716723T3 (pl)
HK (1) HK1200729A1 (pl)
HU (1) HUE041740T2 (pl)
IL (1) IL231614B (pl)
PL (1) PL2760463T3 (pl)
PT (1) PT2760463T (pl)
WO (1) WO2013043720A1 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549967B2 (en) 2009-05-29 2017-01-24 The University Of North Carolina At Chapel Hill Regulation of sodium channels by PLUNC proteins
CA2963142A1 (en) 2014-10-08 2016-04-14 The University Of North Carolina At Chapel Hill Improved peptide inhibitors of sodium channels
US10047051B2 (en) 2015-06-02 2018-08-14 Abbvie S.Á.R.L. Substituted pyridines and method of use
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
MX2018004364A (es) 2015-10-09 2018-08-16 Abbvie Sarl Acidos pirazolo [3,4-b] piridin-6-carboxilicos sustituidos y su uso.
WO2017060879A1 (en) 2015-10-09 2017-04-13 AbbVie S.à.r.l. Novel compounds for treatment of cystic fibrosis
DK3359541T3 (da) 2015-10-09 2020-11-09 Abbvie Overseas Sarl N-sulfonylerede pyrazol[3,4-b]pyridin-6-carboxamider og fremgangsmåde til anvendelse
JP2019512216A (ja) * 2016-02-22 2019-05-16 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル カルシウムチャネルのペプチド阻害剤
AU2017256172A1 (en) 2016-04-26 2018-09-06 AbbVie S.à.r.l. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US20200031866A1 (en) * 2016-09-29 2020-01-30 Spyryx Biosciences, Inc. Peptide inhibitors of sodium channels
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
EP3554527A1 (en) 2016-12-13 2019-10-23 Spyryx Biosciences, Inc. Saline formulations of splunc1 peptides
US20200123137A1 (en) 2016-12-20 2020-04-23 AbbVie S.à.r.l. Deuterated cftr modulators and methods of use
CN106749679A (zh) * 2017-01-10 2017-05-31 中国人民解放军疾病预防控制所 抗P选择素单链抗体靶向抑制物融合蛋白ScFv‑SPLUNC1及其表达方法与应用
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
US11345691B2 (en) 2019-06-03 2022-05-31 AbbVie Global Enterprises Ltd. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US11236067B2 (en) 2019-07-12 2022-02-01 Orphomed, Inc. Compound for treating cystic fibrosis
CA3157798A1 (en) 2019-11-12 2021-05-20 Zhongli Gao 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity
WO2021113806A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021113809A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
EP4274828A1 (en) 2021-01-06 2023-11-15 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US20220213041A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
EP4314010A1 (en) * 2021-03-22 2024-02-07 The University of North Carolina at Chapel Hill Modified peptidomimetics and methods of use
EP4396176A1 (en) 2021-09-03 2024-07-10 Genzyme Corporation Indole compounds and uses thereof in the treatement of cystic fibrosis
CA3230259A1 (en) 2021-09-03 2023-03-09 Junkai Liao Indole compounds and methods of use
WO2024054845A1 (en) 2022-09-07 2024-03-14 Sionna Therapeutics Macrocycic compounds, compositions, and methods of using thereof
WO2024054840A1 (en) 2022-09-07 2024-03-14 Sionna Therapeutics Macrocyclic compounds, compositions, and methods of using thereof
WO2024054851A1 (en) 2022-09-07 2024-03-14 Sionna Therapeutics Macrocyclic compounds, compositions and methods of using thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5162215A (en) 1988-09-22 1992-11-10 Amgen Inc. Method of gene transfer into chickens and other avian species
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JP3056782B2 (ja) 1989-11-03 2000-06-26 ヴァンダービルト ユニバーシティ 標的器官内での遺伝子の発現用医薬組成物
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE316573T1 (de) 1992-10-30 2006-02-15 Gen Hospital Corp Wechselwirkendes fallensystem zur isolierung von proteinen
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
ES2150832B1 (es) 1996-06-12 2001-06-16 Fichtel & Sachs Ag Dispositivo de maniobra para la maniobra, en particular maniobra neumatica, de un embrague de friccion.
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6071533A (en) 1996-11-12 2000-06-06 The Regents Of The University Of California Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
US7384910B2 (en) * 1997-10-08 2008-06-10 Castillo Gerardo M Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
US7790867B2 (en) 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
US20050192221A1 (en) * 2003-12-04 2005-09-01 Mccray Paul B.Jr. Methods and compositions related to plunc polypeptides
US20070161019A1 (en) * 2005-11-04 2007-07-12 Johji Inazawa Method for detecting cancer and a method for suppressing cancer
US7951781B2 (en) 2006-11-02 2011-05-31 University Of Iowa Research Foundation Methods and compositions related to PLUNC surfactant polypeptides
US9549967B2 (en) * 2009-05-29 2017-01-24 The University Of North Carolina At Chapel Hill Regulation of sodium channels by PLUNC proteins

Also Published As

Publication number Publication date
HK1200729A1 (en) 2015-08-14
AU2012312520A1 (en) 2014-05-08
IL231614B (en) 2019-02-28
US9127040B2 (en) 2015-09-08
CA2849267A1 (en) 2013-03-28
US20140228276A1 (en) 2014-08-14
AU2018200871A1 (en) 2018-02-22
BR112014006535A2 (pt) 2017-03-28
EP2760463A4 (en) 2015-07-29
US20160159879A1 (en) 2016-06-09
IL231614A0 (en) 2014-05-28
PT2760463T (pt) 2019-02-27
EP2760463A1 (en) 2014-08-06
HUE041740T2 (hu) 2019-05-28
EP2760463B1 (en) 2018-11-21
DK2760463T3 (en) 2019-03-18
WO2013043720A1 (en) 2013-03-28
ES2716723T3 (es) 2019-06-14

Similar Documents

Publication Publication Date Title
HK1200729A1 (en) Regulation of sodium channels by plunc proteins plunc
IL282393B (en) Production of heterodimeric proteins
PL2742051T3 (pl) Amorficzna postać soli sodowej dolutegrawiru
GB201119694D0 (en) Requirements characterisation
ZA201305972B (en) Method for the preparation of biphephos
ZA201309245B (en) Novel fluoroergoline analogs
GB2502032B (en) Stable Vitamin D3 Composition
SG11201405870SA (en) Process for the preparation of methionine
EP2671565A4 (en) EXTERNAL PREPARATION FOR THE SKIN
HK1198584A1 (en) Process for the preparation of travoprost
PL2723714T3 (pl) Nowe sposoby otrzymywania amidów prostaglandyn
SG11201400939YA (en) Process for the preparation of methoxymelonal
HK1203355A1 (en) Uses of 4-desferrithiocin analogs 4-
EP2729164A4 (en) FORMULATIONS STABILIZING PROTEINS
EP2684869A4 (en) PREPARATION OF 3-MERCAPOTOPROPIONATES
EP2680843A4 (en) DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS
EP2928469A4 (en) POLYMORPHIC FORMS OF DESAZADESFERRITHIOCIN ANALOGS
GB201102913D0 (en) Novel therapeutic
AU2011900644A0 (en) Therapeutic Uses of SLIRP
GB201103169D0 (en) Protein expression
ME03515B (me) Proizvodnja heterodimernih proteina
TWM433588U (en) Structure of plate-constructed cavity
GB201108347D0 (en) Polymprphic form of compound
HUP1100291A2 (en) Process for the preparation of prostaglandin amides
PL394420A1 (pl) Sposób wytwarzania dilauroilofluoresceiny